Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors (Q33414769)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Razelle Kurzrock

19

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

26 July 2017

object named as

Luis H Camacho

17

0 references

Sarina Piha-Paul

object named as

Sarina Piha-Paul

9

0 references

object named as

Siqing Fu

7

0 references

Apostolia Maria Tsimberidou

object named as

Apostolia M Tsimberidou

10

0 references

Ignacio Garrido-Laguna

2

object named as

Ignacio Garrido-Laguna

1 reference

Europe PubMed Central

26 July 2017

5

object named as

Aung Naing

1 reference

Europe PubMed Central

26 July 2017

author name string

David S Hong

1

1 reference

Europe PubMed Central

26 July 2017

Suhendan Ekmekcioglu

3

1 reference

Europe PubMed Central

26 July 2017

Gerald S Falchook

4

1 reference

Europe PubMed Central

26 July 2017

Jennifer J Wheler

6

1 reference

Europe PubMed Central

26 July 2017

Stacy L Moulder

8

1 reference

Europe PubMed Central

26 July 2017

YueJin Wen

11

1 reference

Europe PubMed Central

26 July 2017

Kirk S Culotta

12

1 reference

Europe PubMed Central

26 July 2017

Kenna Anderes

13

1 reference

Europe PubMed Central

26 July 2017

Darren W Davis

14

1 reference

Europe PubMed Central

26 July 2017

Wen Liu

15

1 reference

Europe PubMed Central

26 July 2017

Goldy C George

16

1 reference

Europe PubMed Central

26 July 2017

Susan Percy Ivy

18

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

17 April 2014

1 reference

Europe PubMed Central

26 July 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

26 July 2017

120

1 reference

Europe PubMed Central

26 July 2017

14

1 reference

Europe PubMed Central

26 July 2017

2164-2173

1 reference

Europe PubMed Central

26 July 2017

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

The role of nitric oxide in mediating tumour blood flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

The role of nitric oxide in tumour progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

The biphasic nature of nitric oxide responses in tumor biology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Survival probabilities (the Kaplan-Meier method).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

The role of nitric oxide in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Circulating tumor cells as biomarkers in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

21 January 2018

Tumor iNOS predicts poor survival for stage III melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

7 January 2021

based on heuristic

inferred from DOI database lookup

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28701

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28701

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33414769&oldid=1766079796"